# GLOW Peptide: What the Research on GHK-Cu, BPC-157, and TB-500 Actually Shows > GLOW peptide is a triple blend of GHK-Cu, BPC-157, and TB-500 — three research compounds with decades of preclinical literature between them. A plain-language digest of the published science. GHK-Cu has been shown to upregulate collagen and elastin synthesis across multiple clinical and in vitro models. BPC-157 has accelerated vascular repair and fibroblast proliferation across more than thirty preclinical studies. TB-500 promotes cell migration and blocks fibrotic scarring through distinct actin-regulatory and anti-fibrotic pathways. Each peptide addresses a different phase of the regeneration cascade — and the evidence for each comes from its own body of published literature. ## What Is GLOW Peptide? GLOW peptide is a lyophilized research blend of three distinct compounds: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (body-protecting compound), and TB-500 (a synthetic fragment of thymosin beta-4). The three peptides are combined in a single vial and reconstituted with bacteriostatic water before use. No published preclinical or clinical study has examined the combined GLOW formulation as a whole — every piece of evidence in this digest concerns the three constituents individually, studied in separate published experiments. The rationale for combining them is mechanistic complementarity [22]. GHK-Cu operates primarily at the extracellular matrix level, regulating the genes and enzymes that build and remodel collagen and elastin. BPC-157 drives vascular repair and sensitizes tendon fibroblasts to growth hormone signaling. TB-500 regulates the cytoskeletal dynamics that allow cells to migrate into a wound site and blocks the fibroblast-to-myofibroblast conversion that produces scar tissue. Three phases of repair, three distinct molecular mechanisms, one formulation. The 'legit' in the domain name reflects the question people are actually asking: is the evidence base here real, and is the stated rationale honest? The answer is that the constituent evidence is real — decades of peer-reviewed literature on each peptide, with human clinical data on GHK-Cu and limited but published human trial data on BPC-157. The gap is that no one has yet studied the combination in a controlled setting. This site summarizes what the science does and does not say, cited to source. ## What does the GLOW peptide do? The GLOW blend combines GHK-Cu, BPC-157, and TB-500 — three peptides studied for collagen synthesis, tissue repair, and anti-inflammatory signaling, respectively, across preclinical models. GHK-Cu at concentrations as low as 1–10 nanomolar stimulated procollagen synthesis in human fibroblasts and improved skin density and wrinkle depth in a 12-week clinical study of 41 women [1]. BPC-157 accelerated wound closure, enhanced re-epithelialization, and increased granulation tissue maturity in rat wound models at doses of 10 μg/kg through intraperitoneal, oral, and topical routes equally [11]. TB-500 increased wound reepithelialization by 42–61% at day 4–7 in rat full-thickness wound models and promoted keratinocyte migration 2–3-fold over control at doses as low as 10 picograms [17]. The three pathways do not overlap: GHK-Cu regulates gene expression and extracellular matrix scaffolding, BPC-157 drives angiogenesis and fibroblast sensitization via VEGFR2 and the growth hormone receptor, and TB-500 promotes cellular migration and prevents fibrotic remodeling through actin dynamics and its Ac-SDKP metabolite. Each compound addresses something the other two do not. ## What is GLOW peptide used for in research? In preclinical studies, the three constituents have been examined for skin repair, wound healing, tissue regeneration, anti-inflammatory signaling, hair follicle support, and, in the case of GHK-Cu, neuroprotection in aging animal models. GHK-Cu at 7.5 mg/kg twice daily (intraperitoneal) prevented sleep-deprivation-induced learning impairment in 15-month-old mice and reduced hippocampal inflammatory and oxidative markers [5]. At 15 mg/kg intranasal daily for 8 weeks, it improved spatial memory and reduced axonal damage biomarkers in aged mice of both sexes [6]. BPC-157 in clinical trials as PL14736 showed no adverse effects across limited human studies in IBD, knee pain, and interstitial cystitis [14,15]. TB-500 (thymosin beta-4) has been studied in corneal wound healing, cardiac progenitor activation, and skeletal muscle repair, but has no published human clinical trials in the peer-reviewed literature. ## What peptides make up the GLOW blend? The standard GLOW formulation contains three lyophilized peptides in a single vial: GHK-Cu (molecular weight approximately 340 daltons), BPC-157 (a 15-amino-acid peptide, molecular weight approximately 1,420 daltons), and TB-500 (a synthetic thymosin beta-4 fragment, approximately 4,982 daltons). GHK-Cu is a tripeptide — glycine, histidine, and lysine arranged around a coordinated copper ion — that occurs naturally in human plasma and declines from approximately 200 ng/mL at age 20 to below 60 ng/mL by age 60. BPC-157 is a synthetic sequence derived from a protein isolated from human gastric juice. TB-500 corresponds to a fragment of thymosin beta-4, the intracellular actin-sequestering protein expressed widely in tissue undergoing repair. All three are supplied as lyophilized powders requiring reconstitution with bacteriostatic water before use [22]. ## Why these three together: the blend-synergy rationale The hypothesis driving the GLOW formulation is that GHK-Cu, BPC-157, and TB-500 each address a different stage of the repair and regeneration cascade. GHK-Cu provides the extracellular matrix signal: it upregulates collagen I and III synthesis, modulates matrix metalloproteinases (the enzymes that remodel existing matrix), and affects expression across an estimated 31.2% of human genes in gene-expression analyses, with 59% of affected genes upregulated [2]. BPC-157 amplifies the vascular and fibroblast response: it drives new vessel formation via VEGFR2 upregulation, increases growth hormone receptor expression up to sevenfold in tendon fibroblasts [12], and activates the Src-Caveolin-1-eNOS nitric oxide pathway to promote endothelial cell migration [9]. TB-500 handles the cellular migration problem: it promotes actin polymerization dynamics that allow keratinocytes and myoblasts to move into a wound site, and its Ac-SDKP metabolite blocks fibroblast-to-myofibroblast conversion — the cellular switch that turns healing into fibrosis [20]. The three mechanisms are, in principle, non-overlapping and non-redundant. The scientific gap is that no published controlled study has tested whether the combination produces additive or synergistic effects — that experiment remains to be done. This site summarizes the evidence for each constituent and presents the blend rationale honestly. For more detail on each peptide's mechanism, read the [GLOW peptide benefits](/benefits) page or the full [research literature](/research) digest. --- Three peptide literatures, one reading room — editorial summaries of peer-reviewed research, not clinical guidance.